FDA approval for CR Bard's collagen haemostat:
This article was originally published in Clinica
CR Bard's subsidiary Davol has received US FDA approval to market its Avitene Ultrafoam collagen haemostat, a collagen sponge designed to stop bleeding during surgical procedures by accelerating blood clot formation. Its uses include neurosurgery where topical haemostats are most frequently used. The sponge provides surgeons with better visibility during a surgical procedure by minimising the collection of blood, minimises the patients blood loss and prevents post-operative complications due to haemorrhage, said the Murray Hill, New Jersey-based company.
You may also be interested in...
Biodegradable plastic alternatives for use in cosmetic products were left unaddressed, and thus arguably unusable, under the US Microbead-Free Waters Act enacted in late 2015. European industry stakeholders now face the prospect of a far more extensive microplastic ban, and the viability of bioplastics to replace conventional, petroleum-based microplastics is an area in need of work.
Most of the foreign OTC drug firms targeted in latest warnings FDA published, including the GUM oral care brand manufacturer, were placed on import alert due to GMP violations. Each was inspected by FDA during June, July or May 2019, when the agency was wrapping up an initiative to inspect all previously uninspected drug manufacturers.
AstraZeneca will reacquire Allergan's investigational IL-23 inhibitor brazikumab, and Nestle is to buy its GI drug Zenpep, which had nine-month revenue of $208m.